We developed a robust and reliable GMP-compliant process to enable the manufacturing of a clinical scale product. For advancing the anti-CXCR5 CAR into phase I/IIa, 4.6M€ BMBF-funding was secured to conduct an investigator-initiated trial in collaboration with physicians from the Charité-University Medicine Berlin. Patient enrolment is envisioned for the second half of 2026.

More details regarding the clinical trials CARTemis and/or their scientific founders are involved in can be found at clinicaltrials.gov.